Nexalin Technology Past Earnings Performance
Past criteria checks 0/6
Nexalin Technology has been growing earnings at an average annual rate of 12.7%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 29.2% per year.
Key information
12.7%
Earnings growth rate
36.3%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 29.2% |
| Return on equity | -145.0% |
| Net Margin | -4,197.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nexalin Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -5 | 6 | 0 |
| 30 Sep 23 | 0 | -5 | 5 | 0 |
| 30 Jun 23 | 1 | -2 | 3 | 0 |
| 31 Mar 23 | 1 | -2 | 3 | 0 |
| 31 Dec 22 | 1 | -2 | 3 | 0 |
| 30 Sep 22 | 1 | -2 | 3 | 0 |
| 30 Jun 22 | 1 | -3 | 4 | 0 |
| 31 Mar 22 | 0 | -5 | 5 | 0 |
| 31 Dec 21 | 0 | -6 | 6 | 0 |
| 30 Sep 21 | 0 | -6 | 6 | 0 |
| 30 Jun 21 | 0 | -5 | 5 | 0 |
| 31 Mar 21 | 0 | -4 | 4 | 0 |
| 31 Dec 20 | 0 | -3 | 3 | 0 |
| 31 Dec 19 | 0 | -5 | 2 | 0 |
Quality Earnings: NXL is currently unprofitable.
Growing Profit Margin: NXL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NXL is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.
Accelerating Growth: Unable to compare NXL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).
Return on Equity
High ROE: NXL has a negative Return on Equity (-144.97%), as it is currently unprofitable.